MREO
Price
$2.85
Change
-$0.02 (-0.70%)
Updated
Jun 20 closing price
Capitalization
449.18M
108 days until earnings call
URGN
Price
$14.65
Change
-$0.22 (-1.48%)
Updated
Jun 20 closing price
Capitalization
676.4M
59 days until earnings call
Interact to see
Advertisement

MREO vs URGN

Header iconMREO vs URGN Comparison
Open Charts MREO vs URGNBanner chart's image
Mereo BioPharma Group
Price$2.85
Change-$0.02 (-0.70%)
Volume$1.38M
Capitalization449.18M
UroGen Pharma
Price$14.65
Change-$0.22 (-1.48%)
Volume$3.39M
Capitalization676.4M
MREO vs URGN Comparison Chart in %
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. URGN commentary
Jun 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and URGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 21, 2025
Stock price -- (MREO: $2.83 vs. URGN: $14.67)
Brand notoriety: MREO and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 104% vs. URGN: 96%
Market capitalization -- MREO: $449.18M vs. URGN: $676.4M
MREO [@Biotechnology] is valued at $449.18M. URGN’s [@Biotechnology] market capitalization is $676.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $333.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, MREO is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 5 TA indicator(s) are bullish while URGN’s TA Score has 5 bullish TA indicator(s).

  • MREO’s TA Score: 5 bullish, 4 bearish.
  • URGN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MREO is a better buy in the short-term than URGN.

Price Growth

MREO (@Biotechnology) experienced а +2.36% price change this week, while URGN (@Biotechnology) price change was +21.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.70%. For the same industry, the average monthly price growth was +28.03%, and the average quarterly price growth was +14.56%.

Reported Earning Dates

MREO is expected to report earnings on Oct 07, 2025.

URGN is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+9.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($676M) has a higher market cap than MREO($449M). URGN YTD gains are higher at: 37.746 vs. MREO (-19.286). MREO has higher annual earnings (EBITDA): -44.87M vs. URGN (-119.79M). URGN has more cash in the bank: 196M vs. MREO (62.5M). MREO has less debt than URGN: MREO (747K) vs URGN (125M). URGN has higher revenues than MREO: URGN (91.9M) vs MREO (0).
MREOURGNMREO / URGN
Capitalization449M676M66%
EBITDA-44.87M-119.79M37%
Gain YTD-19.28637.746-51%
P/E RatioN/AN/A-
Revenue091.9M-
Total Cash62.5M196M32%
Total Debt747K125M1%
FUNDAMENTALS RATINGS
MREO vs URGN: Fundamental Ratings
MREO
URGN
OUTLOOK RATING
1..100
1624
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4736
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

URGN's Valuation (74) in the Biotechnology industry is in the same range as MREO (76) in the null industry. This means that URGN’s stock grew similarly to MREO’s over the last 12 months.

MREO's Profit vs Risk Rating (68) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to URGN’s over the last 12 months.

MREO's SMR Rating (98) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (36) in the Biotechnology industry is in the same range as MREO (47) in the null industry. This means that URGN’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for URGN (100) in the Biotechnology industry. This means that MREO’s stock grew significantly faster than URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREOURGN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend about 1 month ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REINX16.98N/A
N/A
Invesco Real Estate Investor
HBLAX14.59N/A
N/A
Hartford Balanced Income A
SSDAX30.98N/A
N/A
DWS Small Cap Growth A
RAAAX10.35N/A
N/A
Altegris/AACA Opportunistic Real Estt A
DUSQX32.81-0.06
-0.18%
DFA US Large Cap Equity Institutional

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with CRNX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-1.57%
CRNX - MREO
48%
Loosely correlated
-1.11%
TRDA - MREO
45%
Loosely correlated
+1.00%
IMTX - MREO
44%
Loosely correlated
-4.19%
KYMR - MREO
44%
Loosely correlated
-1.23%
KOD - MREO
43%
Loosely correlated
+2.27%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with CYYNF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-1.34%
CYYNF - URGN
38%
Loosely correlated
N/A
AIM - URGN
38%
Loosely correlated
+10.96%
MREO - URGN
35%
Loosely correlated
-1.57%
IDYA - URGN
35%
Loosely correlated
-0.87%
ATXS - URGN
34%
Loosely correlated
-0.51%
More